Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
102.02
+0.47 (0.46%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Jazz Pharmaceuticals Stock Forecast
Stock Price Forecast
The 13 analysts with 12-month price forecasts for Jazz Pharmaceuticals stock have an average target of 187.15, with a low estimate of 150 and a high estimate of 230. The average target predicts an increase of 83.44% from the current stock price of 102.02.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Jazz Pharmaceuticals stock from 13 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 7 | 5 |
| Buy | 6 | 6 | 6 | 6 | 7 | 7 |
| Hold | 3 | 3 | 3 | 3 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 14 | 14 | 14 | 15 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $210 | Strong Buy | Reiterates | $210 | +105.84% | Apr 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $200 → $217 | Strong Buy | Maintains | $200 → $217 | +112.70% | Mar 10, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Initiates $175 → $183 | Buy | Initiates | $175 → $183 | +79.38% | Mar 7, 2025 |
| UBS | UBS | Hold → Strong Buy Upgrades $145 → $179 | Hold → Strong Buy | Upgrades | $145 → $179 | +75.46% | Mar 7, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $220 → $230 | Strong Buy | Maintains | $220 → $230 | +125.45% | Mar 6, 2025 |
Financial Forecast
Revenue This Year
4.38B
from 4.07B
Increased by 7.60%
Revenue Next Year
4.53B
from 4.38B
Increased by 3.43%
EPS This Year
23.87
from 8.65
Increased by 175.96%
EPS Next Year
23.56
from 23.87
Decreased by -1.28%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 4.6B | 5.1B | 5.5B | ||
| Avg | 4.4B | 4.5B | 4.8B | ||
| Low | 4.1B | 4.0B | 4.0B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 13.5% | 16.1% | 21.6% | ||
| Avg | 7.6% | 3.4% | 6.4% | ||
| Low | 0.8% | -8.2% | -10.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 25.59 | 26.82 | 28.68 | ||
| Avg | 23.87 | 23.56 | 25.01 | ||
| Low | 22.12 | 19.37 | 16.27 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 195.9% | 12.4% | 21.7% | ||
| Avg | 176.0% | -1.3% | 6.2% | ||
| Low | 155.7% | -18.8% | -31.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.